Related Experiment Video

Updated: Mar 8, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

878

Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression

Hiroaki Sakurai1

  • 1Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|February 4, 2017
PubMed

Insights

Receptor tyrosine kinases (RTKs) are regulated by non-canonical, tyrosine kinase-independent mechanisms. Understanding these pathways, including epidermal growth factor receptor (EGFR), is crucial for developing new cancer therapies and overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Receptor tyrosine kinases (RTKs) are critical regulators of cancer cell growth, migration, and metastasis.
  • Canonical RTK activation occurs through ligand binding and intracellular tyrosine kinase domain activity.
  • Emerging evidence highlights non-canonical, tyrosine kinase-independent regulatory mechanisms involving serine/threonine phosphorylation.

Purpose of the Study:

  • To review recent findings on the non-canonical regulation of specific RTKs, including epidermal growth factor receptor (EGFR), ErbB2, and erythropoietin-producing hepatocellular receptor A2 (EphA2).
  • To discuss the implications of non-canonical RTK activation in cancer progression and resistance to targeted therapies.

Main Methods:

  • This review synthesizes recent research findings.
  • Focuses on the non-canonical regulation of EGFR, ErbB2, and EphA2.
  • Discusses the functional consequences of these regulatory mechanisms in cancer.

Main Results:

  • RTKs are subject to non-canonical regulation through serine/threonine phosphorylation, independent of their kinase activity.
  • Non-canonical activation of EGFR, ErbB2, and EphA2 plays significant roles in cancer progression.
  • These mechanisms contribute to resistance against targeted cancer therapies.

Conclusions:

  • Non-canonical regulation represents a critical, yet understudied, aspect of RTK function in cancer.
  • Further investigation into these pathways is essential for designing novel anti-cancer strategies.
  • Targeting non-canonical RTK regulation may offer new therapeutic avenues for cancer treatment and overcoming drug resistance.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.7K